HeadwaterCompany strategiesBuild yours

Novo Nordisk

Strategic ambitions for 2030, 2026 to 2030

Novo is the global healthcare company that believes lasting health starts now
How Novo describes itself

Strategic ambitions for 2030

Novo Nordisk set out its ambitions for 2030 at a Capital Markets Day in London on 21 September 2026, where it called itself Novo. They replace the Strategic Aspirations 2025, introduced in 2019.

Grow and diversify pipeline

  1. Launch more than five multi-blockbuster medicines by 2030.

  2. Have at least five Phase 3 programmes in obesity and diabetes.

  3. Have at least five Phase 3 programmes in other therapy areas.

  4. Make more than DKK 150 billion of sales from the pipeline in 2035.

Drive sustainable growth

  1. Grow revenue from 2026 to 2030 at a compound annual rate in line with industry peers.

  2. Build enough capacity to treat 10 times more people with obesity on oral GLP-1 medicines.

  3. Serve more than 60 million patients around the world by 2030.

  • Novo Nordisk treated 46 million people living with obesity and diabetes in 2025.
  • Wegovy® pill, launched in the US on 5 January 2026, had passed 5 million US prescriptions by August.
  • Sales grew 10% at constant exchange rates to DKK 309.1 billion in 2025.
  • Obesity care sales grew 31% at constant exchange rates to DKK 82.3 billion.

Deliver attractive returns

  1. Keep the operating margin broadly stable.

  2. Keep paying an attractive dividend per share.

  • Operating profit was DKK 127.7 billion in 2025, about 41% of sales.
  • The total dividend for 2025 was DKK 11.70 a share.
  • Free cash flow was DKK 28.3 billion in 2025.

More than 60 million patients by 2030

Novo Nordisk treated 46 million people with its diabetes and obesity care products in 2025.,

0.0m

people treated in the 12 months to June 2026

  • Diabetes care, 41.6 million
  • Obesity care, 4.9 million
  • The ambition
  • A bead for every half a million people
  • People treated with obesity care products rose by 69% in the 12 months to June 2026, to 4.9 million.
  • Wegovy® had launched in around 60 countries by June 2026.

Obesity care sales passed the 2025 target more than three times over

The Strategic Aspirations 2025 were introduced in 2019 and ran to the end of 2025. Two of them had a figure to reach: obesity care sales above DKK 25 billion, and more than a third of the diabetes market by value.

More than DKK 25 billion in obesity care sales by 2025
2019DKK 6bn2025DKK 82.3bnTargetMore than DKK 25bn
0102030405060708090
More than a third of the diabetes market by value
202433.7%202530.1%TargetMore than a third
0510152025303540
DKK 309bn
Sales in 2025, more than double 2019’s: 17% a year
DKK 128bn
Operating profit in 2025, more than double 2019’s: 16% a year
DKK 306bn
Returned to shareholders from 2020 to 2025
46m
People treated in 2025, about 16 million more than in 2019
+19%
Emissions across scopes 1, 2, and 3 in 2025, against 2024

Sources

  1. Every ambition belongs to a pillar.

    There is no separate list of targets: the nine ambitions are split between the three pillars, so each pillar can be judged by its own numbers. We recommend this layout when each pillar has one person leading it.

  2. Some ambitions have no figure to check.

    Revenue growth in line with industry peers can only be judged once the peers have reported. A broadly stable margin and an attractive dividend have no figure at all. We recommend a figure, or a comparison with your own starting point, such as the 2025 margin of about 41%, so the company can check its own progress.

  3. The last plan’s targets turned out very differently.

    The Strategic Aspirations 2025 asked for more than DKK 25 billion of obesity care sales by 2025 and more than a third of the diabetes market by value. In 2025, obesity care sales were DKK 82.3 billion, and the diabetes value share was 30.1%. We recommend checking every target at each year’s planning, and changing any that no longer ask the right thing of the company.

Sources

  1. 1. Novo Nordisk A/S (2026). Highlights to be presented at Novo’s Capital Markets Day 2026. Company announcement, 21 September 2026. globenewswire.com
  2. 2. Novo Nordisk A/S (2026). Financial report for the period 1 January 2026 to 30 June 2026. Company announcement No 48 / 2026, 4 August 2026. sec.gov
  3. 3. Novo Nordisk A/S (2026). Strategic Aspirations 2025. Annual Report 2025. annualreport.novonordisk.com
  4. 4. Novo Nordisk A/S (2026). Financial performance. Annual Report 2025. annualreport.novonordisk.com

Headwater is not connected with Novo Nordisk A/S. Novo Nordisk and Novo are trade marks of their owners. Updated 28 September 2026.

All company strategies